HealthQuill Articles by: HealthQuill
Swiss healthcare multinational F. Hoffmann-La Roche AG will acquire US-based 89bio Inc. for a deal worth up to $3.5 billion to expand its metabolic disease portfolio.
Drugs Health Pharma

Roche to buy 89bio Inc for $3.5 billion to expand metabolic disease portfolio

Swiss healthcare multinational F. Hoffmann-La Roche AG will acquire US-based 89bio Inc. for a deal worth up to $3.5 billion to expand its

Read More
Merck & Co. got approval from the US Food and Drug Administration for a pill to treat a rare type of tumour in adults and children aged above 12 years, according to a statement.
Health Research

India’s cancer burden: Rising cases and gender disparities

HQ Team September 17, 2025: A recent comprehensive study based on data from India’s National Cancer Registry Programme has highlighted significant regional variations

Read More
AstraZeneca’s lung cancer drug, Tagrisso, reduced the risk of death by 51% in the early stages of the disease, according to a company statement.
Drugs Health

AstraZeneca’s asthma drug fails end-stage trial in COPD

HQ Team September 17, 2025: AstraZeneca’s asthma drug Fasenra (benralizumab) has  failed to meet its primary goal in a Phase III trial for

Read More
https://www.novartis.com/research-and-development/research-disease-areas/cardiovascular-and-metabolic-disease-research-novartis
Drugs Health Pharma

Novartis signs $5.2 billion pact with China’s Argo Biopharmaceutical

HQ Team September 4, 2025: China’s Argo Biopharmaceutical Co., Ltd., and Switzerland’s Novartis AG have inked a $5.2 billion pact to develop new

Read More
About 1.1 billion people globally are living with a mental disorder, mostly anxiety and depression disorders that together accounted for more than two-thirds of such conditions in 2021, according to two reports from the World Health Organization.
Health Pharma Research

‘In 2021, 1.1 billion people worldwide were living with mental disorders’

About 1.1 billion people globally are living with a mental disorder, mostly anxiety and depression disorders that together accounted for more than two-thirds

Read More
Swedish-British AstraZeneca Plc’s medicine baxdrostat lowered blood pressure in trial patients during an end-stage study, and the company plans to file for regulatory approvals by the end of the year.
Drugs Health Pharma

AstraZeneca’s medicine lowers BP, to file for early approvals

Swedish-British AstraZeneca Plc’s medicine baxdrostat lowered blood pressure in trial patients during an end-stage study, and the company plans to file for regulatory

Read More
The USFDA has granted a standard approval for Eisai and Biogen's Alzheimer injection, Leqembi —the first treatment to secure the traditional approval, paving the way for wider insurance coverage of the drug.
Drugs

FDA warns Alzheimer patients on Leqembi to seek earlier scanning

HQ Team August 30, 2025: The U.S. Food and Drug Administration (FDA) is recommending an additional magnetic resonance imaging in Alzheimer’s disease patients

Read More
Johnson & Johnson has stopped a mid-trial evaluation of a combination drug to treat people with a type of arthritis after the therapy failed to show “sufficient evidence” of benefit to the patients.
Drugs Health Pharma

J & J stops rheumatoid arthritis trial due to lack of ‘sufficient evidence’

Johnson & Johnson has stopped a mid-trial evaluation of a combination drug to treat people with a type of arthritis after the therapy

Read More
Britain’s Medicines and Healthcare products Regulatory Agency has approved GSK Plc’s Blujepa, an oral antibiotic pill to treat uncomplicated urinary tract infections in females above 12 years and older, weighing at least 40 kilograms.
Drugs Health Pharma

GSK drug gets Britain’s nod to treat UTI patients 12 years and above

Britain’s Medicines and Healthcare products Regulatory Agency has approved GSK Plc’s Blujepa, an oral antibiotic pill to treat uncomplicated urinary tract infections in

Read More
Biogen Inc., a US-based biotechnology company, got a nod from Britain’s medicines regulator for its drug to treat postnatal depression in adults.
Drugs Health Pharma

Biogen’s drug to treat postnatal depression gets UK regulator’s nod

Biogen Inc., a US-based biotechnology company, got a nod from Britain’s medicines regulator for its drug to treat postnatal depression in adults.

Read More